KAIST spin-off developing PEGylated bilirubin BX-001N to prevent acute kidney injury after cardiac surgery, now in phase 2a in Korea.
Korean acute-kidney-injury drug at Series A — therapeutic with clinical milestones similar to BioSapien's profile.
Evidence from the records
- “pre-Series A extension”
- “Drug for acute kidney injury”
- “BX-001N: phase 1 completed (51 volunteers, Australia), phase 2a under way in Korea (NCT07164833) with KDDF support.”
- Intro path
- Founder-to-founder intro via BioSapien (network portfolio company of Globivest).
- First step
- Qualify Globivest via BioSapien first.